Literature DB >> 28225739

Damage control laparotomy utilization rates are highly variable among Level I trauma centers: Pragmatic, Randomized Optimal Platelet and Plasma Ratios findings.

Justin Jeremiah Joseph Watson1, Jamison Nielsen, Kyle Hart, Priya Srikanth, John D Yonge, Christopher R Connelly, Phillip M Kemp Bohan, Hillary Sosnovske, Barbara C Tilley, Gerald van Belle, Bryan A Cotton, Terence S OʼKeeffe, Eileen M Bulger, Karen J Brasel, John B Holcomb, Martin A Schreiber.   

Abstract

BACKGROUND: Damage control laparotomy (DCL) is intended to limit deleterious effects from trauma-induced coagulopathy. DCL has been associated with mortality reduction, but may increase complications including sepsis, abscess, respiratory failure, hernia, and gastrointestinal fistula. We hypothesized that (1) DCL incidence would vary between institutions; (2) mortality rates would vary with DCL rates; (3) standard DCL criteria of pH, international normalized ratio, temperature and major intra-abdominal vascular injury would not adequately capture all patients.
METHODS: Trauma patients at 12 Level 1 North American trauma centers were randomized based on transfusion ratios as described in the Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial. We analyzed outcomes after emergent laparotomy using a mixed-effects logistic model comparing DCL versus definitive surgical management with random effect for study site. Primary outcomes were 24-hour and 30-day mortality.
RESULTS: Three hundred twenty-nine patients underwent emergent laparotomy: 213 (65%) DCL and 116 (35%) definitive surgical management. DCL rates varied between institutions (33-83%), (p = 0.002). Median Injury Severity Score (ISS) was higher in the DCL group, 29 (interquartile range, 13-34) versus 21 (interquartile range, 22-41) (p < 0.001). Twenty-four-hour mortality was 19% with DCL versus 4% (p < 0.001); 30-day mortality was 28% with DCL versus 19% (p < 0.001). In a mixed-effects model, ISS and major intra-abdominal vascular injury were correlates of DCL (odds ratio [OR], 1.05; 95% confidence interval [CI], 1.02-1.07 and OR, 2.7; 95% CI, 1.4-5.2). DCL was not associated with 30-day mortality (OR, 2.33; 95% CI, 0.97-5.60). Correlates included ISS (OR, 1.06; 95% CI, 1.02-1.09), PRBCs in 24 hours (OR, 1.10; 95% CI, 1.03-1.18), and age (OR, 1.04; 95% CI, 1.01-1.06). No significant mortality difference was detected between institutions (p = 0.63). Sepsis and VAP occurred more frequently with DCL (p < 0.05). Eighty percent (135/213) of DCL patients met standard criteria.
CONCLUSION: Although DCL utilization varied significantly between institutions, there was no significant mortality difference between centers. This finding suggests tempering DCL use may not decrease mortality, but could decrease related complications. LEVEL OF EVIDENCE: Therapeutic study, level III.

Entities:  

Mesh:

Year:  2017        PMID: 28225739      PMCID: PMC5325087          DOI: 10.1097/TA.0000000000001357

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  19 in total

1.  Complications after 344 damage-control open celiotomies.

Authors:  Richard S Miller; John A Morris; Jose J Diaz; Michael B Herring; Addison K May
Journal:  J Trauma       Date:  2005-12

2.  Current use of damage-control laparotomy, closure rates, and predictors of early fascial closure at the first take-back.

Authors:  Quinton M Hatch; Lisa M Osterhout; Asma Ashraf; Jeanette Podbielski; Rosemary A Kozar; Charles E Wade; John B Holcomb; Bryan A Cotton
Journal:  J Trauma       Date:  2011-06

3.  Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.

Authors:  John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle
Journal:  JAMA       Date:  2015-02-03       Impact factor: 56.272

Review 4.  Trauma patients at risk for massive transfusion: the role of scoring systems and the impact of early identification on patient outcomes.

Authors:  Sundeep Burman; Bryan A Cotton
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

5.  To close or not to close, that is one of the questions? Perceptions of Trauma Association of Canada surgical members on the management of the open abdomen.

Authors:  Shahzeer Karmali; D Evans; Kevin B Laupland; C Findlay; Chad G Ball; Eric Bergeron; T Charyk Stewart; N Parry; S Khetarpal; Andrew W Kirkpatrick
Journal:  J Trauma       Date:  2006-02

6.  Time to laparotomy for intra-abdominal bleeding from trauma does affect survival for delays up to 90 minutes.

Authors:  John R Clarke; Stanley Z Trooskin; Prashant J Doshi; Lloyd Greenwald; Charles J Mode
Journal:  J Trauma       Date:  2002-03

7.  Has evolution in awareness of guidelines for institution of damage control improved outcome in the management of the posttraumatic open abdomen?

Authors:  Juan A Asensio; Patrizio Petrone; Gustavo Roldán; Eric Kuncir; Emily Ramicone; Linda Chan
Journal:  Arch Surg       Date:  2004-02

8.  'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury.

Authors:  M F Rotondo; C W Schwab; M D McGonigal; G R Phillips; T M Fruchterman; D R Kauder; B A Latenser; P A Angood
Journal:  J Trauma       Date:  1993-09

9.  A prospective observational study of abdominal injury management in contemporary military operations: damage control laparotomy is associated with high survivability and low rates of fecal diversion.

Authors:  Iain M Smith; Zine K M Beech; Jonathan B Lundy; Douglas M Bowley
Journal:  Ann Surg       Date:  2015-04       Impact factor: 12.969

10.  An outcome prediction model for exsanguinating patients with blunt abdominal trauma after damage control laparotomy: a retrospective study.

Authors:  Shang-Yu Wang; Chien-Hung Liao; Chih-Yuan Fu; Shih-Ching Kang; Chun-Hsiang Ouyang; I-Ming Kuo; Jr-Rung Lin; Yu-Pao Hsu; Chun-Nan Yeh; Shao-Wei Chen
Journal:  BMC Surg       Date:  2014-04-28       Impact factor: 2.102

View more
  5 in total

1.  New non-invasive device to promote primary closure of the fascia and prevent loss of domain in the open abdomen: a pilot study.

Authors:  Joao Baptista Rezende-Neto; Bruna Gewehr Camilotti
Journal:  Trauma Surg Acute Care Open       Date:  2020-11-11

2.  Outcome of trauma-related emergency laparotomies, in an era of far-reaching specialization.

Authors:  Falco Hietbrink; Diederik Smeeing; Steffi Karhof; Henk Formijne Jonkers; Marijn Houwert; Karlijn van Wessem; Rogier Simmermacher; Geertje Govaert; Miriam de Jong; Ivar de Bruin; Luke Leenen
Journal:  World J Emerg Surg       Date:  2019-08-14       Impact factor: 5.469

3.  Evidence for use of damage control surgery and damage control interventions in civilian trauma patients: a systematic review.

Authors:  Derek J Roberts; Niklas Bobrovitz; David A Zygun; Andrew W Kirkpatrick; Chad G Ball; Peter D Faris; Henry T Stelfox
Journal:  World J Emerg Surg       Date:  2021-03-11       Impact factor: 5.469

4.  Variation in use of damage control laparotomy for trauma by trauma centers in the United States, Canada, and Australasia.

Authors:  Derek J Roberts; Peter D Faris; Chad G Ball; Andrew W Kirkpatrick; Ernest E Moore; David V Feliciano; Peter Rhee; Scott D'Amours; Henry T Stelfox
Journal:  World J Emerg Surg       Date:  2021-10-14       Impact factor: 5.469

5.  Physiology dictated treatment after severe trauma: timing is everything.

Authors:  Karlijn J P van Wessem; Luke P H Leenen; Falco Hietbrink
Journal:  Eur J Trauma Emerg Surg       Date:  2022-02-26       Impact factor: 2.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.